LUIS GONZAGA
PAZ-ARES RODRÍGUEZ

2024

1. A potential therapeutic strategy based on acute oxidative stress induction for wild-type NRF2/KEAP1 lung squamous cell carcinoma

   Redox Biology, Vol. 75

2. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

   Annals of Oncology, Vol. 35, Núm. 9, pp. 805-816

3. Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study

   Journal of Thoracic Oncology, Vol. 19, Núm. 2, pp. 285-296

4. CD4+ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts

   OncoImmunology, Vol. 13, Núm. 1

5. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

   Nature Communications, Vol. 15, Núm. 1

6. Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 2, pp. 192-204

7. Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 2, pp. 180-191

8. Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial

   Lung Cancer, Vol. 189

9. Correction to: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments (Drugs, (2024), 84, 5, (527-548), 10.1007/s40265-024-02030-7)

   Drugs

10. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

    Journal of Clinical Oncology

11. Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries

    The Lancet Regional Health - Europe, Vol. 38

12. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

    Nature Medicine, Vol. 30, Núm. 1, pp. 271-278

13. Durvalumab _ Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden

    Clinical Cancer Research, Vol. 30, Núm. 4, pp. 824-835

14. Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach

    Archives of pathology & laboratory medicine, Vol. 148, Núm. 3, pp. 318-326

15. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study

    BMC Cancer, Vol. 23, Núm. Suppl 1

16. Expert-based collaborative analysis of the situation and prospects of biomarker test implementation in oncology in Spain

    Clinical and Translational Oncology, Vol. 26, Núm. 4, pp. 985-990

17. Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT)

    Lung Cancer, Vol. 187

18. Facts and Hopes on Cancer Immunotherapy for Small Cell Lung Cancer

    Clinical Cancer Research, Vol. 30, Núm. 14, pp. 2872-2883

19. Farnesyltransferase inhibition overcomes oncogene-addicted non-small cell lung cancer adaptive resistance to targeted therapies

    Nature Communications, Vol. 15, Núm. 1

20. First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study

    Cancer research communications, Vol. 4, Núm. 6, pp. 1609-1619